Opko Health Inc.’s busy first half of 2013 continued April 24 with the announcement that it will acquire Israel’s Opko Biologics in an all-stock transaction valued at roughly $480 million.
The deal, expected to close during the second half of this year, is structured so that Prolor’s management and personnel...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?